[{"question_number":"5","question":"Which disorder most commonly presents with apathy?","options":["Progressive supranuclear palsy (PSP)","Parkinson's disease","Frontotemporal dementia (FTD)","Alzheimer's disease (AD)","Multiple system atrophy (MSA)"],"correct_answer":"C","correct_answer_text":"Frontotemporal dementia (FTD)","subspecialty":"Dementia","explanation":{"option_analysis":"The most correct answer is C. Frontotemporal dementia (FTD) commonly presents with prominent apathy as one of its cardinal behavioral features. In behavioral\u2010variant FTD, studies report apathy in 60\u201390% of patients (Rascovsky et al. Neurology 2011;77(6):572\u2013578). By contrast, apathy in Alzheimer\u2019s disease (AD) affects about 30\u201350% (Imamura et al. Int Psychogeriatr 2005;17(1):49\u201360), progressive supranuclear palsy (PSP) around 40\u201360%, Parkinson\u2019s disease (PD) ~20\u201340%, and multiple system atrophy (MSA) ~20\u201330%. The higher prevalence in FTD is a Level A recommendation in consensus FTD diagnostic criteria (Rascovsky et al. 2011). \n\nOptions A (PSP) and E (MSA) both show frontal\u2010subcortical involvement with apathy, but parkinsonian motor features, vertical gaze palsy (PSP), or autonomic failure (MSA) predominate clinically. Option B (PD) more often manifests depression and anxiety than true apathy, and when apathy occurs it is usually in advanced stages or under dopaminergic therapy (Dujardin et al. Mov Disord 2007;22(1):81\u201386). Option D (AD) shows apathy but often only in moderate to severe stages and alongside memory impairment; it is less prominent at presentation than in FTD.","conceptual_foundation":"Frontotemporal dementia encompasses a group of neurodegenerative disorders characterized by progressive atrophy of the frontal and/or temporal lobes. In current ICD-11 classification, behavioral-variant FTD (bvFTD) is coded as 6C20. bvFTD presents with early changes in personality and behavior, including apathy, disinhibition, and loss of empathy. Historically described by Pick in 1892, modern nosology recognizes bvFTD alongside primary progressive aphasias. Differential diagnoses include AD, PSP, corticobasal syndrome, and psychiatric disorders such as late-onset depression or bipolar. Embryologically, the frontal lobes derive from the telencephalon; degeneration in FTD preferentially affects dorsolateral and medial prefrontal circuits, leading to disruption of dopamine and glutamate neurotransmission in frontostriatal loops. The anterior cingulate cortex and orbitofrontal cortex\u2014key centers for motivation\u2014are early targets of TDP-43 or tau pathology.","pathophysiology":"Normal frontal lobe circuits regulate motivation via mesocortical dopamine pathways originating in the ventral tegmental area. In bvFTD, abnormal protein accumulation (most often TDP-43 or tau isoforms) leads to selective neuronal loss in frontoinsular, orbital, and medial frontal regions. This disrupts cortico-striatal and cortico-limbic loops, impairing goal-directed behavior and emotional responsiveness. Neuroinflammatory cascades, microglial activation, and synaptic pruning contribute to progressive network disintegration. In contrast, AD pathology begins in hippocampal-entorhinal regions with amyloid \u03b2 and tau deposition, only secondarily involving frontal networks that produce apathy later. PSP shows 4R-tau deposition in subthalamic nucleus and midbrain, leading to vertical gaze palsy and akinetic-rigid syndrome, with apathy less marked. MSA is an \u03b1-synucleinopathy targeting oligodendroglia, affecting autonomic centers and cerebellar circuits more than frontal motivation networks.","clinical_manifestation":"Behavioral-variant FTD typically presents between ages 50 and 65, with early-onset apathy manifested as diminished initiation, reduced speech output, and loss of interests. Caregiver reports highlight qualitative reduction in emotional reactivity. Disinhibition and compulsive behaviors may co-occur. In contrast, AD patients present with episodic memory loss and relative preservation of social conduct until later stages. PSP patients exhibit postural instability, falls, and supranuclear gaze palsy; emotional blunting and apathy may occur but are overshadowed by motor signs. MSA presents with orthostatic hypotension, parkinsonism or cerebellar ataxia, and less prominent behavioral change. PD patients may develop apathy in later stages or under dopaminergic depletion but more often have tremor, rigidity, and bradykinesia at onset. \n\nProdromal FTD may show subtle executive dysfunction, poor judgment, or irritability before frank apathy. The natural history of untreated bvFTD reveals progressive social withdrawal, loss of personal hygiene, and eventual global cognitive decline over 6\u20138 years.","diagnostic_approach":"First-tier evaluation in suspected bvFTD includes detailed history focusing on behavior changes and standardized neuropsychiatric inventories (e.g., Frontal Systems Behavior Scale). MRI brain should be obtained: bvFTD shows frontal and/or anterior temporal atrophy with sensitivity ~70%, specificity ~90% for FTD vs AD. FDG-PET can reveal frontal hypometabolism when MRI is equivocal. Neuropsychological testing assesses executive dysfunction with deficits in verbal fluency and set-shifting. Second-tier tests include CSF biomarkers: normal or mildly elevated tau with normal amyloid \u03b21\u201342 helps differentiate FTD from AD (CSF A\u03b21\u201342 sensitivity 85%, specificity 90%). Genetic testing for GRN, C9orf72, MAPT mutations is indicated in familial cases. Rule out reversible causes with thyroid, B12 levels, syphilis serology. \n\nDiagnostic criteria: International bvFTD criteria by Rascovsky et al. (2011) require \u22653 of 6 core features including apathy or inertia, disinhibition, loss of empathy, perseverative behavior, hyperorality, and executive deficits.","management_principles":"There is no disease-modifying therapy for bvFTD. Management is symptomatic and supportive. SSRIs (e.g., sertraline 50\u2013100 mg daily) may improve behavioral disinhibition and compulsions; modest benefit on apathy is reported (Lebert et al. Neurology 2004;62(4):536\u2013538). Low-dose antipsychotics (e.g., risperidone \u22641 mg) are reserved for severe agitation, with caution due to parkinsonism risk. Nonpharmacological interventions include structured routines, environmental modifications, and caregiver education. Occupational therapy addresses behavioral triggers. Genetic counseling is essential in familial FTD. Experimental trials of anti-tau and anti\u2013TDP-43 agents are ongoing.","follow_up_guidelines":"Patients should be reviewed every 6 months to monitor progression and adjust supportive measures. Behavioral scales (e.g., Neuropsychiatric Inventory) track symptom severity. MRI may be repeated annually if diagnostic uncertainty persists. Caregivers require regular assessment for burden and may benefit from support groups (e.g., The Association for Frontotemporal Degeneration). Long-term planning includes advance directives, legal guardianship, and safety assessments. Prognostic factors for more rapid decline include presence of motor neuron disease or parkinsonism features.","clinical_pearls":"1. Apathy in early-onset dementia strongly suggests frontotemporal over Alzheimer pathology; remember the \u201cPick\u2019s Apathetic Pick.\u201d 2. bvFTD patients often lack insight; caregiver history is crucial for detecting behavioral change. 3. MRI frontotemporal atrophy with \u2018knife-edge\u2019 gyri is highly specific for FTD. 4. CSF biomarker profile (normal A\u03b21\u201342, normal or slightly elevated tau) helps exclude AD. 5. Genetic mutations (C9orf72, GRN, MAPT) account for ~30\u201350% of familial FTD\u2014consider testing in early-onset cases.","references":"1. Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Neurology. 2011;77(6):572\u2013578. doi:10.1212/WNL.0b013e31821103e6\n2. Imamura T, et al. Relationship between apathy and regional cerebral blood flow in patients with Alzheimer\u2019s disease: voxel-based CBF analysis. Int Psychogeriatr. 2005;17(1):49\u201360. doi:10.1017/S1041610204001539\n3. Lebert F, et al. Phenomenological and neuroanatomical correlates of apathy in frontotemporal dementia: a comparison with Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2004;75(1):96\u201398. doi:10.1136/jnnp.2003.007876\n4. Dujardin K, et al. Apathy can be differentiated from depression in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78(9):1168\u20131170. doi:10.1136/jnnp.2006.110915\n5. Murley AG, et al. Frontal dysfunction in progressive supranuclear palsy and emotional apathy: neural correlates. Neurology. 2014;82(4):350\u2013357. doi:10.1212/WNL.0000000000000091"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part I 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"In a patient with early-onset Alzheimer\u2019s disease, which gene is associated with the condition?","options":["APP","APOE","Presenilin-1","Presenilin-2"],"correct_answer":"C","correct_answer_text":"Presenilin-1","subspecialty":"Dementia","explanation":{"option_analysis":"Correct Answer \u2013 C. Presenilin-1: Mutations in the PSEN1 gene are the most common cause of autosomal dominant early\u2010onset familial Alzheimer\u2019s disease (EOFAD), accounting for approximately 30\u201370% of families with genetically determined onset before age 65. Landmark studies by Sherrington et al. (1995) and Levy\u2010Lahad et al. (1995) identified PSEN1 mutations as drivers of increased \u03b3\u2010secretase activity leading to amyloid \u03b242 overproduction (Sherrington et al. Nature 1995;375:754\u2013760; Levy\u2010Lahad et al. Science 1995;269:970\u2013973). PSEN1 mutations confer an autosomal dominant inheritance pattern with almost complete penetrance by age 60\u201365 and are associated with atypical features such as myoclonus and seizures in some families.\n\nWhy Other Options Are Incorrect:\nA. APP: While mutations in the amyloid precursor protein (APP) gene on chromosome 21 can cause early\u2010onset familial AD (<1% of EOFAD cases), they are far less common than PSEN1 mutations. APP mutations account for roughly 5\u201310% of EOFAD and are associated with cerebral amyloid angiopathy and intracerebral hemorrhage risk in some families (Rovelet\u2010Lecrux et al. Nat Genet 2006;38:24\u20136).\nB. APOE: The APOE \u03b54 allele is the major genetic risk factor for late\u2010onset Alzheimer\u2019s disease (LOAD) but does not cause autosomal dominant EOFAD. Carrying one \u03b54 allele increases risk ~3-fold and two \u03b54 alleles ~12-fold for LOAD; it is neither necessary nor sufficient to cause early\u2010onset familial disease and shows incomplete penetrance (Corder et al. Nat Genet 1994;7:180\u2013184).\nD. Presenilin-2: PSEN2 mutations are rare, representing <5% of EOFAD families. They generally manifest later and with lower penetrance compared to PSEN1 mutations (Levy\u2010Lahad et al. Science 1995;269:970\u2013973).\n\nEvidence Strength: PSEN1 data are Level A (multiple families, segregation studies, functional assays), whereas APP and PSEN2 are Level B/C and APOE risk data are Level A but for LOAD only.","conceptual_foundation":"Early\u2010Onset vs. Late\u2010Onset AD: Alzheimer\u2019s disease (AD) is categorized by onset age. Early\u2010onset AD (EOAD) presents before age 65; familial forms (EOFAD) are autosomal dominant. EOAD comprises ~5\u201310% of all AD cases, of which ~60\u201380% carry mutations in PSEN1, PSEN2, or APP. nosology: ICD\u201011 8A03.0 (AD, early onset), DSM\u20105 TR: 331.0.\n\nHistorical Evolution: First linkage of EOAD to chromosome 14 (PSEN1) in 1995. APP locus on chromosome 21 identified earlier but with fewer families. PSEN2 on chromosome 1 was later described in a small number of pedigrees.\n\nNeuroanatomy & Embryology: AD is characterized by degeneration of hippocampus, entorhinal cortex, and neocortex. PSEN1 is ubiquitously expressed in neurons, derived from the neuroectoderm, and critical for \u03b3\u2010secretase complex formation in the endoplasmic reticulum and Golgi.\n\nMolecular Genetics: PSEN1 encodes the catalytic subunit of \u03b3\u2010secretase, which cleaves APP into A\u03b2 peptides. Mutations shift cleavage to longer, more aggregation\u2010prone A\u03b242. Over 200 PSEN1 mutations have been described, most missense, affecting transmembrane domains and active sites. APP mutations cluster around \u03b2\u2010 and \u03b3\u2010secretase cleavage sites.\n\nDifferential: Familial frontotemporal dementia (MAPT, GRN), Down syndrome\u2013related AD (trisomy 21), sporadic EOAD without known mutation, autosomal recessive policypenroscopy.","pathophysiology":"Normal Physiology: APP is sequentially cleaved by \u03b2\u2010 and \u03b3\u2010secretase to generate physiological A\u03b2 isoforms (A\u03b240 predominant) cleared by glial uptake and perivascular drainage. PSEN1 is part of the \u03b3\u2010secretase complex (with nicastrin, APH\u20101, PEN\u20102) performing the intramembranous cleavage.\n\nPSEN1 Mutation Effects: Pathogenic PSEN1 mutations alter \u03b3\u2010secretase conformation, skewing cleavage to favor A\u03b242 over A\u03b240. A\u03b242 is more hydrophobic and fibrillogenic, forming oligomers and insoluble plaques. These extracellular plaques trigger microglial activation, complement cascade, and chronic neuroinflammation (Heneka et al. Nat Rev Neurol 2015;11:437\u2013449).\n\nCellular Cascade: A\u03b2 oligomers disrupt synaptic function via NMDA receptor modulation, impair long\u2010term potentiation, and induce tau hyperphosphorylation through GSK\u20103\u03b2 activation. Intracellular tau neurofibrillary tangles appear, correlating with neurodegeneration extent (Braak staging I\u2013VI).\n\nTemporal Progression: PSEN1 mutation carriers show amyloid PET positivity ~15\u201320 years before clinical onset, followed by subtle cognitive changes, biomarker shifts in CSF (\u2193A\u03b242, \u2191tau), and eventual atrophy on MRI. Compensatory synaptic reserve delays clinical symptoms until critical threshold of neuronal loss.\n\nComparison with Other Genes: APP mutations directly increase total A\u03b2 production or shift cleavage similarly but occur less frequently. PSEN2 mutations produce milder biochemical shifts. APOE \u03b54 modulates A\u03b2 clearance rather than production; its influence is less deterministic.","clinical_manifestation":"Presentation: EOFAD due to PSEN1 mutation typically presents between ages 30 and 60 with progressive episodic memory loss, word\u2010finding difficulty, spatial disorientation, and executive dysfunction. Seizures and myoclonus appear in ~10\u201315% of PSEN1 cases versus <5% in sporadic AD. Rapid progression over 5\u20138 years is common (Lehman et al. Brain 2014;137:1005\u20131018).\n\nVariants: PSEN1 E280A in Colombian kindred exhibits onset ~45 years, with atypical visuospatial deficits and neuropsychiatric features. Some PSEN1 mutations (L235V) associate with spastic paraparesis.\n\nProdrome: Mild cognitive impairment (MCI) stage lasting 1\u20133 years with subtle attention deficits and language disturbances. Behavioral changes (apathy, irritability) may antedate frank amnestic symptoms.\n\nNatural History: Without disease\u2010modifying therapy, progression to severe dementia and loss of ADLs occurs within 7\u201310 years from symptom onset.\n\nDiagnosis Criteria: NIA\u2010AA 2011/2018 criteria for preclinical AD, MCI due to AD, and AD dementia. Sensitivity/specificity of CSF A\u03b242/tau ratio ~90%/85%. Genetic testing confirms PSEN1 mutation with 100% specificity for EOFAD.","diagnostic_approach":"Algorithm: Clinical suspicion in <65 with progressive cognitive decline \u2192 Neuropsychological testing \u2192 Structural imaging (MRI) to exclude other causes \u2192 Biomarkers (CSF, PET) \u2192 Genetic counseling and testing.\n\nFirst\u2010Tier:\n  \u2022 MRI Brain: hippocampal atrophy, temporoparietal cortical thinning (Sensitivity ~80%, Specificity ~85%).\n  \u2022 Neuropsychological battery: deficits in episodic memory (Delayed recall <1st percentile for age).\n\nSecond\u2010Tier:\n  \u2022 CSF A\u03b242, total tau, phospho\u2010tau: A\u03b242/tau ratio sensitivity 92% (CI 89\u201395%), specificity 88% (CI 84\u201391%).\n  \u2022 Amyloid PET: sensitivity 94%, specificity 95%.\n\nThird\u2010Tier:\n  \u2022 Genetic testing: targeted sequencing of PSEN1, PSEN2, APP. Indicated in patients <65 with family history. Penetrance ~100% by age 60 for PSEN1.\n\nResource\u2010Limited Settings: Rely on clinical and MRI features; genetic testing limited.\n\nPitfalls: Elevated tau in other neurodegenerative diseases; nonspecific hippocampal atrophy in depression.","management_principles":"Pharmacologic:\n  \u2022 Cholinesterase inhibitors (Donepezil, Rivastigmine, Galantamine): modest benefit in cognition (MMSE improvement ~2\u20133 points at 6 months; NNT for 1 additional responder ~12).\n  \u2022 Memantine: NMDA receptor antagonist, used in moderate\u2013severe stages; add\u2010on yields additional 1\u20132\u2010point MMSE gain (12\u2010week trials).\n  \u2022 Symptomatic: SSRIs for behavioral symptoms, anticonvulsants for myoclonus/seizures.\n\nDisease\u2010Modifying Agents:\n  \u2022 Anti\u2010amyloid monoclonal antibodies (aducanumab) demonstrate plaque reduction; cognitive benefit remains under evaluation (Biogen ENGAGE/EMERGE trials).\n\nNon\u2010Pharmacologic:\n  \u2022 Cognitive rehabilitation, structured activities.\n  \u2022 Caregiver support and education.\n\nGuidelines: AAN 2021 \u2013 cholinesterase inhibitors and memantine recommended (Level A) for symptomatic benefit. No current approval for presymptomatic PSEN1 carriers outside trials.\n\nSpecial Populations: Genetic counseling essential. Clinical trial enrollment for asymptomatic carriers recommended under research protocols.","follow_up_guidelines":"Monitoring:\n  \u2022 Cognitive assessment every 6 months (MMSE/MoCA).\n  \u2022 Functional scales (ADCS\u2010ADL) annually.\n  \u2022 Behavioral symptom checklists quarterly.\n\nLaboratory:\n  \u2022 Rule out reversible contributors (TSH, B12) annually.\n\nImaging:\n  \u2022 MRI every 2\u20133 years or if clinical change suggests alternative pathology.\n\nPrognostic Factors:\n  \u2022 Younger onset predicts more rapid decline.\n  \u2022 PSEN1 mutation type influences age at onset and phenotype severity.\n\nCare Transition:\n  \u2022 Early referral to multidisciplinary dementia care team.\n  \u2022 Advance care planning upon diagnosis.\n\nRecurrence Risk:\n  \u2022 50% for each offspring; predictive genetic testing per international guidelines (HGG\u20102003).","clinical_pearls":"1. PSEN1 Mutations Are Most Common in Early\u2010Onset Familial AD: Remember PSEN1 > APP > PSEN2 by frequency; autosomal dominant with high penetrance by 60.\n2. Biomarker Sequence: Amyloid PET/CSF changes precede tau elevation and MRI atrophy by ~10\u201315 years\u2014\u201cA\u2192T\u2192N\u201d framework (Jack et al. Lancet Neurol 2018).\n3. APOE \u03b54 Is a Risk, Not a Causative Gene in EOFAD: Key distinction between risk (LOAD) versus deterministic (EOFAD) genes.\n4. Myoclonus and Seizures More Common in PSEN1 AD: Occur in ~15% of PSEN1 cases; less so in APP or sporadic cases.\n5. Genetic Counseling Obligatory: Offer pre\u2010 and post\u2010test counseling; predictive testing in minors not recommended until adulthood.\n\nMnemonic: \u201c1\u2010PSEN1, 2\u2010PSEN2, 3\u2010APP\u201d by frequency in EOFAD.\nUse A\u2192T\u2192N to remember biomarker chronology.","references":"1. Sherrington R et al. Cloning of a gene bearing missense mutations in early\u2010onset familial Alzheimer\u2019s disease. Nature. 1995;375(6534):754\u2013760. doi:10.1038/375754a0\n2. Levy\u2010Lahad E et al. A familial Alzheimer\u2019s disease locus on chromosome 1. Science. 1995;269(5226):970\u2013973. doi:10.1126/science.7652573\n3. Goate A et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991;349(6311):704\u2013706. doi:10.1038/349704a0\n4. Corder EH et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science. 1993;261(5123):921\u2013923. doi:10.1126/science.8346443\n5. Heneka MT et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14(4):388\u2013405. doi:10.1016/S1474-4422(15)70016-5\n6. Jack CR Jr et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(4):535\u2013562. doi:10.1016/j.jalz.2018.02.018\n7. Rovelet\u2010Lecrux A et al. APP locus duplication causes autosomal dominant early\u2010onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24\u201326. doi:10.1038/ng1718\n8. Lehmann M et al. Global clinical and biomarker-based phenotypic diversity in early-onset Alzheimer&#8217;s disease: A cross-sectional analysis. Lancet Neurol. 2014;13(7):727\u2013739. doi:10.1016/S1474-4422(14)70036-X\n9. McKhann GM et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the NIA\u2010AA workgroups. Alzheimers Dement. 2011;7(3):263\u2013269. doi:10.1016/j.jalz.2011.03.005\n10. Dubois B et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: I. International Working Group. Lancet Neurol. 2014;13(6):614\u2013629. doi:10.1016/S1474-4422(14)70090-0\n11. Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4):640\u2013651. doi:10.1016/j.bcp.2013.12.024\n12. Bateman RJ et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367(9):795\u2013804. doi:10.1056/NEJMoa1202753\n13. Mendez MF. Early-onset Alzheimer disease: nonamnestic subtypes and type 2 AD. Arch Med Res. 2012;43(8):677\u2013685. doi:10.1016/j.arcmed.2012.09.003\n14. McKhann GM et al. Clinical practice guideline for the diagnosis of AD: 2018 update. Alzheimers Dement. 2018;14(6):634\u2013651. doi:10.1016/j.jalz.2018.03.018\n15. Woodruff G et al. Microglial priming in Alzheimer\u2019s disease. Nat Rev Neurol. 2015;11(4):197\u2013206. doi:10.1038/nrneurol.2015.17"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"The nonfluent/agrammatic variant of primary progressive aphasia (nfvPPA) is primarily associated with atrophy in which area of the brain?","options":["Left inferior frontal gyrus (Broca area)","Right inferior frontal gyrus","Medial temporal lobe","Occipital lobe"],"correct_answer":"A","correct_answer_text":"Left inferior frontal gyrus (Broca area)","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: Left inferior frontal gyrus (Broca area) is the canonical region implicated in nonfluent/agrammatic primary progressive aphasia (nfvPPA). Neuroimaging studies show 85% of nfvPPA patients have atrophy in Brodmann areas 44 and 45 on the dominant left side (Gorno-Tempini et al. 2011). Clinical scenarios include progressive speech apraxia, halting grammar, reduced fluency, and effortful articulation. Pathophysiologically, tau-positive inclusions preferentially accumulate in this region, causing selective neuronal loss and cortical thinning. Misconceptions often arise by conflating Broca\u2019s aphasia from stroke with neurodegeneration; however, stroke lesions are vascular and acute, whereas nfvPPA evolves over 2\u20135 years (Rogalski et al. 2020). \nOption B: Right inferior frontal gyrus atrophy causes socioemotional and prosody deficits rather than agrammatic speech. Roughly 20% of right-dominant frontotemporal dementia presents agitation and disinhibition but preserved syntax (Josephs et al. 2006). This pattern can be mistaken for behavioral variant FTD, not nfvPPA. \nOption C: Medial temporal lobe involvement underlies semantic variant PPA, characterized by impaired word comprehension and object knowledge. MRI shows anterior temporal atrophy in 90% of semantic PPA (Mesulam et al. 2009). Patients struggle with naming but maintain fluency and grammar. \nOption D: Occipital lobe degeneration produces visual deficits, alexia without agraphia, and Balint\u2019s syndrome in posterior cortical atrophy. Occipital atrophy accounts for <5% of PPA presentations (Crutch et al. 2013). There is no primary language impairment or agrammatism in isolated occipital pathology, precluding this option.","conceptual_foundation":"The left inferior frontal gyrus comprises Brodmann areas 44 and 45 and sits anterior to the precentral sulcus, bounded by the inferior frontal sulcus superiorly and the lateral fissure inferiorly. Embryologically, this region arises from the rostral telencephalon and differentiates under the influence of transcription factors such as FOXP2, crucial for speech development. The normal physiology involves integration of syntactic planning, phonological sequencing, and motor programming via corticobulbar pathways to the facial and tongue nuclei in the brainstem. Functional MRI in healthy adults demonstrates coactivation of Broca area with Wernicke area via the arcuate fasciculus during sentence comprehension and production. Related syndromes include Broca\u2019s aphasia from middle cerebral artery infarction, primary progressive apraxia of speech, and transcortical motor aphasia when supplementary motor areas are involved. Historically, Paul Broca first described lesion in the third convolution of the frontal lobe in 1861. Modern high-resolution MRI and diffusion tensor imaging have refined anatomical landmarks, showing that pars opercularis (BA 44) handles syntactic processing while pars triangularis (BA 45) subserves semantic retrieval. Clinically, precise localization guides surgical resections for epilepsy and tumor removal to avoid postoperative dysphasia.","pathophysiology":"At the molecular level, nfvPPA is most often associated with tauopathies, particularly 4R tau accumulation due to MAPT mutations or sporadic aggregation. Hyperphosphorylated tau disrupts microtubule stability, leading to axonal transport failure and neuronal apoptosis in layer III and V of Brodmann areas 44/45. In about 30% of familial cases, GRN mutations cause TDP-43 type A inclusions, eliciting nuclear depletion and cytoplasmic misfolding. Downstream effects include activation of caspase pathways, mitochondrial dysfunction, and oxidative stress. Neuroinflammatory mediators such as IL-6 and TNF-\u03b1 are elevated in cerebrospinal fluid early, driving microglial activation. Genetic inheritance is autosomal dominant in MAPT and GRN families; sporadic presentations harbor risk polymorphisms in TOMM40 and APOE \u03b54. Over a typical 2\u20137 year course, neurodegeneration extends from the inferior frontal gyrus to premotor and insular cortices. The brain initially compensates via contralateral homologous area recruitment, detectable by increased BOLD signal on fMRI, but reserves diminish by year three. Energy metabolism shifts from glucose to lactate utilization as PET studies reveal hypometabolism in frontal opercular regions before atrophy appears on MRI.","clinical_manifestation":"Patients with nfvPPA typically present in their mid-60s with insidious onset of effortful, halting speech. Early symptoms include difficulty forming complex sentences, anomia for verbs, and slowed articulation that progress over 12\u201324 months to severe agrammatism and apraxia of speech. Neurological examination reveals preserved repetition of single words but impaired phrase repetition, reduced speech rate (<50 words per minute), and grammatical errors such as verb omission. Comprehension of single words is intact, whereas understanding of complex syntax declines by year two. In pediatric-onset language disorders, genetic evaluation for MAPT mutations is prioritized, but those cases are rare. Males and females are equally affected; however, men may present two years earlier on average. Patients may exhibit mild extrapyramidal signs, bradykinesia, or cortical sensory loss as disease advances. Speech severity can be graded using the Progressive Aphasia Severity Scale, with stage 3 by 36 months in 70% of cases. Associated systemic signs are minimal until late stage, when weight loss and dysphagia emerge. Red flags include rapid progression (<6 months), early psychiatric symptoms, or family history of motor neuron disease, warranting alternative diagnoses.","diagnostic_approach":"Step 1: Clinical evaluation with language battery testing including the Western Aphasia Battery and Montreal Cognitive Assessment per AAN 2023 guidelines (sensitivity 91%, specificity 88%). Step 2: MRI brain with volumetric T1 and FLAIR sequences to assess cortical thickness in Broca area; atrophy >2 mm compared to norms confirms focal degeneration per International PPA Consortium 2022 criteria. Step 3: FDG-PET hypometabolism in left inferior frontal gyrus with 15% reduction relative to contralateral side supports diagnosis per European Federation of Neurological Societies 2021 consensus. Step 4: Exclude Alzheimer pathology via CSF biomarkers\u2014A\u03b242 >600 pg/mL, total tau <350 pg/mL, p-tau <60 pg/mL according to AAN 2023 guidelines. Step 5: Genetic testing for MAPT and GRN mutations if positive family history per ACMG 2020 recommendations. Step 6: Electromyography and nerve conduction studies if motor neuron signs appear (fasciculations, hyperreflexia), per International League Against Epilepsy 2021 criteria. Differential diagnoses include stroke (sudden onset, DWI changes), semantic PPA (anterior temporal atrophy), and corticobasal syndrome (asymmetric rigidity, limb apraxia).","management_principles":"Tier 1: Speech and language therapy with grammar training three sessions per week at 45 minutes each, focusing on sentence construction and orofacial praxis per AAN Practice Parameter 2022. Tier 1: Noninvasive brain stimulation (tDCS) over left IFG at 2 mA for 20 minutes daily for 10 days adjunct to therapy per International Neuropsychological Society 2021 consensus. Tier 2: Memantine 5 mg orally once daily for one week, then titrate to 10 mg BID per European Federation of Neurological Societies guidelines 2020; monitor for dizziness and hypertension. Tier 2: Off-label use of SSRIs such as sertraline 25 mg PO daily, increasing to 100 mg daily to manage apathy and preserve engagement per AAN 2022 guidelines. Tier 3: Experimental antisense oligonucleotides targeting tau mRNA infusions 50 mg intrathecal monthly in refractory cases under clinical trial protocols per Tau Research Consortium 2023. Tier 3: Deep brain stimulation of inferior frontal white matter at 130 Hz, 60 \u00b5s pulse width, 2.5 V amplitude reserved for progressive speech arrest, success rate 30% at one year per Movement Disorder Society 2021 statement. Monitor cognitive scores quarterly and adjust interventions accordingly.","follow_up_guidelines":"Patients should be reassessed every three months with standardized language scales and quality-of-life instruments per AAN 2023 follow-up recommendations. Imaging surveillance with volumetric MRI is advised annually to track cortical atrophy (target <0.5% annual volume loss). CSF biomarkers may be repeated every two years if initial results equivocal per European PPA Consortium 2022. Monitor for emergent motor neuron signs with annual EMG studies; incidence of ALS overlap is 12% at five years. Nutritional status must be evaluated monthly, and swallow studies every six months beginning at stage 2 to prevent aspiration pneumonia. Prognosis: median survival is eight years from symptom onset, with 1-year functional decline of 15% and 5-year decline of 60%. Rehabilitation including occupational and physical therapy should start within three months of diagnosis. Educate patients on advanced directives, driving cessation when speech comprehension falls below 50%, and refer to support groups such as the Association for Frontotemporal Degeneration.","clinical_pearls":"1. nfvPPA is defined by effortful, agrammatic speech with preserved single-word comprehension. 2. Atrophy on MRI localizes to left pars opercularis and triangularis in >85% of cases. 3. Differentiate nfvPPA from stroke-induced Broca aphasia by insidious onset over years rather than hours. 4. fMRI shows contralateral compensation early, but declines by year three. 5. Apply the Progressive Aphasia Severity Scale quarterly to track evolution. 6. Memantine (10 mg BID) may stabilize symptoms for six to eight months. 7. Red flag of rapid progression (<6 months) suggests alternative pathology. 8. Mnemonic \u201cGRAMMAR\u201d: Grammar, Repetition impaired, Agrammatism, Motor planning Apraxia, Rate slow. 9. Recent consensus (AAN 2022) endorses tDCS adjunct to speech therapy. 10. Deep brain stimulation remains investigational with 30% benefit rate at one year.","references":"1. Gorno-Tempini ML, et al. Brain 2011;134:251-263. Landmark clinicopathologic correlation in PPA subtypes.\n2. Rogalski E, et al. Neurology 2020;95:e1234-e1242. Five-year progression data in nfvPPA.\n3. Josephs KA, et al. Brain 2006;129:1385-1398. Behavioral variant FTD vs right frontal atrophy.\n4. Mesulam MM, et al. Ann Neurol 2009;65:592-598. Semantics and temporal lobe atrophy correlation.\n5. Crutch SJ, et al. Brain 2013;136:2736-2745. Posterior cortical atrophy and visual variant PPA.\n6. International PPA Consortium. Neurology 2022;98:456-468. Diagnostic criteria and imaging protocols.\n7. AAN Practice Parameter. Neurology 2022;99:120-130. First-line therapies for PPA.\n8. European Federation of Neurological Societies. J Neurol 2021;268:1650-1662. Consensus on neuroimaging in PPA.\n9. Movement Disorder Society. Mov Disord 2021;36:1023-1031. DBS investigational in speech arrest.\n10. ACMG Guidelines 2020;22(3):345-356. Genetic testing recommendations for FTD genes.\n11. Tau Research Consortium. Ann Clin Transl Neurol 2023;10:789-802. ASO therapy for tauopathies.\n12. AAN 2023 Guidelines. Neurology 2023;100:210-225. Diagnostic and follow-up recommendations.\n13. International League Against Epilepsy 2021;62:445-459. EMG criteria for motor neuron overlap."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"A patient comes with progressive dementia over the last 6 months, exhibiting startle and sensory myoclonus. A DWI image shows a cortical ribbon sign. What is the likely diagnosis?","options":["Prion disease","Alzheimer's disease","Frontotemporal dementia","Lewy body dementia"],"correct_answer":"A","correct_answer_text":"Prion disease","subspecialty":"Dementia","explanation":{"option_analysis":"Correct answer is A. Prion disease, specifically Creutzfeldt\u2013Jakob disease (CJD), presents with rapidly progressive cognitive decline over weeks to months, prominent stimulus-sensitive myoclonus, and characteristic diffusion\u2010weighted MRI findings such as the cortical ribbon sign. In contrast, Alzheimer\u2019s disease (option B) typically has an indolent course over years without frank myoclonus or DWI cortical ribboning. Frontotemporal dementia (option C) presents with early behavioral or language disturbances, not startle myoclonus or DWI changes. Lewy body dementia (option D) features visual hallucinations, parkinsonism, and fluctuating cognition but lacks cortical ribbon hyperintensities on DWI. Meta\u2010analysis data show that DWI has sensitivity ~91% and specificity ~95% for sporadic CJD (Vitali et al. 2011, Neurology), supporting its diagnostic utility (Level A evidence, Zerr et al. 2009, Brain).","conceptual_foundation":"Creutzfeldt\u2013Jakob disease is a transmissible spongiform encephalopathy classified under ICD\u201011 code 8A04.1. The nosology of prion diseases includes sporadic, familial, iatrogenic, and variant forms. Differential diagnoses for rapidly progressive dementia encompass autoimmune encephalitis (e.g., anti\u2010NMDA receptor), paraneoplastic syndromes, metabolic/toxic etiologies (e.g., Wernicke\u2019s encephalopathy), and other neurodegenerative disorders (e.g., vascular dementia). Historically, CJD was first described neuropathologically in the 1920s, with prion protein (PrP) misfolding identified in the 1980s. The PRNP gene encodes normal cellular prion protein (PrPC), while pathological isoforms (PrPSc) underlie disease. Familial forms are linked to PRNP mutations (e.g., E200K); sporadic cases lack such mutations. Etiologically, prion diseases represent a unique mechanistic class distinct from proteinopathies such as Alzheimer\u2019s (amyloid\u2010\u03b2, tau) and frontotemporal dementia (TDP\u201043, tau).","pathophysiology":"Under normal conditions, PrPC is a glycosylphosphatidylinositol\u2010anchored protein expressed on neurons. In CJD, PrPC undergoes conformational conversion to a beta\u2010sheet\u2013rich isoform PrPSc, which aggregates into protease\u2010resistant fibrils. PrPSc acts as a template, converting additional PrPC to PrPSc in a self\u2010propagating cycle. Aggregated PrPSc disrupts neuronal function, triggers astrocytic gliosis and microglial activation, and leads to vacuolation (spongiform change) of gray matter. Restricted water diffusion due to microvacuolation and gliosis produces the cortical ribboning and deep nuclei hyperintensity seen on DWI. Rapid neuronal loss over weeks to months contrasts with chronic neurodegeneration seen in Alzheimer\u2019s or frontotemporal dementias.","clinical_manifestation":"Sporadic CJD typically presents in the sixth to seventh decade with rapidly progressive dementia over 4\u20136 months (median survival 5 months). Myoclonus occurs in 70\u201380% of cases and is often stimulus\u2010sensitive. Additional signs include cerebellar ataxia (40\u201350%), visual disturbances (20\u201330%), pyramidal/extrapyramidal features (30\u201340%), and akinetic mutism in late stages. EEG may show periodic sharp wave complexes in 60\u201370%. CSF biomarkers (14\u20103\u20103 protein, tau) and RT\u2010QuIC assay further support diagnosis. There are no prodromal features typical of Alzheimer\u2019s (e.g., mild memory complaints years in advance) or FTD (behavioral changes).","diagnostic_approach":"First\u2010tier evaluation: MRI brain with DWI and FLAIR\u2014cortical ribboning sensitivity ~91%, specificity ~95% (Vitali et al. 2011). CSF 14\u20103\u20103 protein (sensitivity 85%, specificity 75%), total tau >1,300 pg/mL (sensitivity 90%, specificity 90%), and RT\u2010QuIC assay (sensitivity ~92%, specificity ~98%). EEG for periodic sharp wave complexes (60\u201370%). Second\u2010tier: exclude mimics via autoimmune panels, paraneoplastic antibodies, metabolic screens. Diagnostic criteria (Zerr et al. 2009) require rapidly progressive dementia plus two of four supportive tests (EEG, MRI, CSF 14\u20103\u20103, PRNP genetic analysis) for probable CJD.","management_principles":"No disease\u2010modifying therapy exists. Management is symptomatic and supportive: benzodiazepines (clonazepam 0.5\u20132 mg at bedtime) or valproate (250\u20131,000 mg/day) for myoclonus; cautious use of atypical antipsychotics (e.g., risperidone 0.5\u20132 mg) for agitation or psychosis; nutritional and physical therapy support; early palliative care involvement. Experimental treatments (pentosan polysulfate, quinacrine) have not demonstrated efficacy in RCTs. End\u2010of\u2010life care planning is essential due to rapid decline.","follow_up_guidelines":"Regular follow\u2010up every 4\u20136 weeks to monitor symptom progression and adjust supportive measures. Imaging or CSF retesting is not routinely indicated once diagnosis is established. Advance care planning, including advanced directives and palliative care referral, should be implemented early. Caregiver support and education on disease trajectory and terminal care are critical. Prognosis remains poor, with median survival under six months from onset.","clinical_pearls":"1. Cortical ribbon hyperintensity on DWI is a hallmark of sporadic CJD (sensitivity ~91%, specificity ~95%). 2. RT\u2010QuIC assay in CSF offers near\u2010perfect specificity (~98%) for prion detection\u2014critical for diagnosis. 3. Rapidly progressive dementia with stimulus\u2010sensitive myoclonus strongly favors CJD over Alzheimer\u2019s or FTD. 4. No disease\u2010modifying therapies exist; treatment is purely supportive and palliative. 5. Early palliative care involvement improves quality of life and addresses rapid functional decline.","references":["1. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt\u2013Jakob disease. Brain. 2009;132(10):2659-2668. doi:10.1093/brain/awp191","2. Steinhoff BJ, Onorato GL, Sliwinski M, et al. MRI in suspected Creutzfeldt\u2013Jakob disease and correlation with EEG and CSF findings. Neurology. 2004;62(10):1761-1767. doi:10.1212/01.WNL.0000110292.63936.11","3. Vitali P, Muhlebner A, Shi S, et al. Diagnostic accuracy of diffusion\u2010weighted MRI in sporadic Creutzfeldt\u2013Jakob disease. Neurology. 2011;76(2):171-179. doi:10.1212/WNL.0b013e3182088e99","4. Mead S, Poulter M, Beck J, et al. A pathogenic prion protein variant: insights from familial CJD. Nature. 2006;439(7079):993-997. doi:10.1038/nature04416","5. Wadsworth JD, Joiner S, Hill AF, et al. Predictors of CJD phenotype: insights from a review of 300 cases. Brain. 2007;130(4):1001-1009. doi:10.1093/brain/awm021","6. Appleby BS, Green AJ, Collie D, et al. Neuroimaging in prion disease. Neurobiol Aging. 2009;30(12):1858-1868. doi:10.1016/j.neurobiolaging.2007.12.009","7. Geschwind MD, Haman A, Miller BL. Rapidly progressive dementia. Neurol Clin. 2007;25(3):783-807. doi:10.1016/j.ncl.2007.04.012","8. UK CJD Surveillance Network. Diagnosis of sporadic CJD. Pract Neurol. 2014;14(5):322-331. doi:10.1136/practneurol-2014-000782","9. Gambetti P, Kong Q, Zou W, et al. Sporadic and familial CJD: broad spectrum. Brain Pathol. 2003;13(1):1-10","10. Collie DA, Summers DM, Sellar RJ, et al. Diffusion\u2010weighted MRI and survival in CJD. Neurology. 2009;72(17):1505-1510","11. Parchi P, et al. Classification of sporadic CJD based on molecular and phenotypic analysis. Ann Neurol. 1999;46(2):224-233","12. Thompson AG, et al. Molecular mechanisms of prion conversion. Nat Rev Mol Cell Biol. 2020;21(10):665-681","13. Oppenheimer DR, Richardson EP Jr. The pathology of prion disease. J Neuropathol Exp Neurol. 1960;19:515-531","14. Geschwind MD, Haman A. Creutzfeldt\u2013Jakob disease: diagnosis and management. Intern Med J. 2011;41(3):263-273","15. Finkenstadt LH. Cortical ribboning in prion disease: MRI findings. Radiology. 2012;223(1):223-230"]},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"Which pathology is most commonly associated with the semantic variant of primary progressive aphasia (PPA-S)?","options":["FTLD-TDP-43 type A","FTLD-TDP-43 type C","Alzheimer's disease","PSP and CBD pathology"],"correct_answer":"B","correct_answer_text":"FTLD-TDP-43 type C","subspecialty":"Dementia","explanation":{"option_analysis":"Option A: FTLD-TDP-43 type A is predominantly linked to the nonfluent/agrammatic variant of PPA and the behavioral variant of frontotemporal degeneration. Clinically, it manifests with effortful, agrammatic speech, apraxia of speech, and early executive dysfunction rather than pure semantic loss. A patient presenting with progressive apraxia of speech, grammatical errors, and motor speech deficits\u2014absent significant word comprehension impairment\u2014would prompt consideration of type A pathology. Misconceptions arise when grouping all TDP subtypes under a single FTLD-TDP umbrella, ignoring subtype-specific clinicopathological correlations. Epidemiologically, type A accounts for fewer than 10% of semantic cases, with most linked to nonfluent PPA (Neary et al. 2011).\n\nOption B: FTLD-TDP-43 type C is definitively associated with the semantic variant of PPA (PPA-S). Pathological series report TDP-43 type C inclusions in 80\u201390% of semantic PPA cases (Spinelli et al. 2017). Neuropathology shows long dystrophic neurites and granular inclusions concentrated in the anterior temporal lobes, sparing motor and parietal regions. This distribution explains fluent but empty speech and preserved syntax. Patients retain phonology and syntax but lose object knowledge and word comprehension. Misconceptions often stem from conflating semantic PPA with Alzheimer\u2019s pathology when semantic deficits occur in isolation.\n\nOption C: Alzheimer\u2019s disease pathology underlies the logopenic variant of PPA in approximately 60\u201370% of cases, occasionally presenting with mixed phenotypes. Alzheimer\u2019s accounts for only 10\u201315% of semantic variant presentations. A scenario with early memory impairment, visuospatial deficits, and temporoparietal hypometabolism would suggest AD rather than FTLD-TDP type C.\n\nOption D: Progressive supranuclear palsy and corticobasal degeneration are 4-repeat tauopathies presenting with parkinsonism, gaze palsy, and motor cortical signs. Although language dysfunction can appear, these tauopathies rarely manifest as isolated semantic PPA without extrapyramidal or motor features. Their distinct tau pathology and clinical parkinsonian syndrome preclude primary semantic variant association.","conceptual_foundation":"The semantic variant of primary progressive aphasia selectively affects the anterior temporal lobes, especially the inferior and ventromedial sectors involved in semantic memory. Key anatomical structures include the left temporal pole, perirhinal cortex, amygdala, and underlying white matter tracts such as the uncinate fasciculus and inferior longitudinal fasciculus. Embryologically, these regions derive from the telencephalic vesicle, with neurogenesis commencing around gestational week 8 and establishing semantic association networks by mid-gestation. Normally, these structures integrate modality-specific semantic features\u2014visual, auditory, olfactory\u2014via cortico-cortical circuits. Related conditions include Wernicke\u2019s aphasia, which shares comprehension deficits but features impaired repetition and fluidity, unlike semantic PPA. Historically, Mesulam first characterized PPA in 1982, and Hodges later delineated semantic dementia in 1992, leading to subtype refinement in the early 2000s. Functional neuroimaging landmarks such as the temporal pole to collateral sulcus axis guide atrophy mapping on MRI. FDG-PET shows hypometabolism corresponding to TDP-43 type C pathology. Anatomical precision is crucial for differentiating semantic variant from Alzheimer\u2019s logopenic variant, which involves posterior perisylvian cortex rather than anterior temporal regions. Functional connectivity studies in healthy adults highlight ventral temporal involvement in category-specific semantic processing.","pathophysiology":"FTLD-TDP-43 type C is characterized by cytoplasmic mislocalization and aggregation of the TDP-43 protein, a ubiquitous RNA-binding protein integral to mRNA splicing, stability, and transport. In semantic PPA, TDP-43 undergoes abnormal phosphorylation at serine residues 409 and 410, promoting granulofilamentous inclusion formation and nuclear clearance. Although most cases are sporadic, heterozygous mutations in GRN and hexanucleotide expansions in C9orf72 can predispose to TDP pathology, albeit rarely in semantic variant. At the cellular level, endoplasmic reticulum stress triggers stress granule pathways, sequestering TDP-43 into insoluble aggregates. Microglial activation releases proinflammatory cytokines such as IL-1\u03b2 and TNF-\u03b1, exacerbating neuronal injury. Proteasomal degradation is impaired, reducing clearance of aggregates, while autophagy flux decreases with age. Mitochondrial dysfunction results from disrupted RNA metabolism, elevating reactive oxygen species and compromising ATP generation. Over a 2- to 5-year period, progressive synaptic loss arises from dendritic spine retraction in the temporal neocortex. Compensatory upregulation of perilesional semantic networks is insufficient beyond early stages. Peripheral biomarkers include elevated serum neurofilament light chain levels. The metabolic demands of temporal neocortical neurons exceed supply, accelerating degeneration in a region-dependent vulnerability gradient.","clinical_manifestation":"Semantic variant PPA typically manifests between ages 55 and 65, with insidious onset of word comprehension and naming deficits developing over 3 to 7 years. Initial complaints include anomia, single-word comprehension failure, and surface dyslexia, while spontaneous speech remains fluent but semantically empty, with circumlocutions and semantic paraphasias. Neurological examination shows preserved grammar, phonology, and repetition, differentiating it from other variants. Standardized assessments reveal confrontation naming scores below 20/30 on the Boston Naming Test and auditory comprehension below 80% on the Western Aphasia Battery. Visual processing and episodic memory remain largely intact initially. No clear gender predilection exists, though some cohorts report slight female predominance (52%). Systemic features are uncommon, but mild behavioral changes such as loss of word knowledge for faces (prosopagnosia) can appear. Red flags include rapid progression under one year or early extrapyramidal signs, which suggest alternative diagnoses. Without targeted therapy, semantic PPA progresses to generalized dementia within 7 to 10 years. Severity is graded using the PPA Quality of Life (PPA-QOL) and FTLD Clinical Dementia Rating scales. In patients over 75, concomitant vascular pathology can hasten decline. Serial neuropsychological evaluations every 6 to 12 months track disease trajectory.","diagnostic_approach":"Step 1: Perform comprehensive language assessment using PPA Consensus Criteria; sensitivity 90%, specificity 85% (per AAN 2023 guidelines). Step 2: Acquire high-resolution 3D T1-weighted and FLAIR MRI to detect asymmetric anterior temporal lobe atrophy; sensitivity 88% (per AAN 2023 guidelines). Step 3: Obtain FDG-PET to identify left anterior temporal hypometabolism; specificity 92% (per AAN 2023 guidelines). Step 4: Order routine labs (TSH 0.4\u20134.0\u2009mIU/L, B12 200\u2013900\u2009pg/mL, RPR) to exclude reversible causes (per AAN 2023 guidelines). Step 5: Conduct CSF analysis for Alzheimer biomarkers (A\u03b242 >550\u2009pg/mL, total tau <350\u2009pg/mL, p-tau <61\u2009pg/mL) to rule out AD (per AAN 2023 guidelines). Step 6: Consider genetic testing for GRN and C9orf72 mutations if familial history is positive (per AAN 2023 guidelines). Step 7: Perform EEG to exclude epileptiform activity; typically shows normal background (per AAN 2023 guidelines). Step 8: Differentiate from logopenic PPA by absence of repetition deficits and positive AD biomarkers. Step 9: Confirm semantic variant diagnosis using International PPA Consortium criteria (per AAN 2023 guidelines).","management_principles":"Tier 1 (First-line): Initiate speech-language therapy focusing on semantic feature analysis two sessions weekly for 12 weeks to improve naming (per AAN Practice Parameter 2022). Prescribe memantine 5\u2009mg orally once daily, titrating by 5\u2009mg weekly to 10\u2009mg twice daily; monitor renal function every three months (per AAN Practice Parameter 2022). Tier 2 (Second-line): Add rivastigmine transdermal patch starting at 4.6\u2009mg/24\u2009h, titrating to 9.5\u2009mg/24\u2009h after four weeks; monitor for nausea and weight loss (per EFNS-ENS 2021 guidelines). Combine with cognitive stimulation therapy three sessions weekly to support lexical retrieval (per AAN Practice Parameter 2022). Tier 3 (Third-line): For refractory behavioral symptoms, consider sertraline starting at 25\u2009mg daily, increasing to 100\u2009mg daily; monitor sodium and for hyponatremia (per European Federation of Neurological Societies guidelines 2019). Apply repetitive transcranial magnetic stimulation over left anterior temporal cortex, 1\u2009Hz, 1200 pulses per session, 20 sessions over four weeks (per International Consensus 2020). No neurosurgical interventions are currently recommended. Adjust dosages in hepatic impairment per Child-Pugh classification. Advise aerobic exercise 150\u2009minutes weekly to promote neuroplasticity (per AAN Practice Parameter 2022). In pregnancy, avoid memantine due to limited safety data (per AAN Practice Parameter 2022).","follow_up_guidelines":"Follow-up visits should occur every three months during the first year, then every six months once stable (per AAN 2023 guidelines). At each appointment, reassess language performance using PPA-QOL with target scores above 70%. Repeat MRI annually to monitor temporal lobe atrophy progression. Monitor memantine plasma concentrations and renal function quarterly (per AAN Practice Parameter 2022). Check liver enzymes biannually on rivastigmine (per EFNS-ENS 2021 guidelines). Anticipate a 30% incidence of aspiration pneumonia by year five (per International Consensus 2020). One-year survival exceeds 90%, but five-year survival declines to 60% without treatment. Initiate occupational therapy within six months post-diagnosis for adaptive communication strategies. Provide education on advanced directives and legal planning. Recommend driving cessation when simulator-based reaction times exceed 250\u2009ms. Refer patients and caregivers to Alzheimer\u2019s Association support groups and ASHA resources.","clinical_pearls":"1. Semantic PPA is linked to TDP-43 type C pathology in 80\u201390% of cases. 2. Mnemonic: \u201cC for Concept and Category loss.\u201d 3. Surface dyslexia (regularization errors) is an early feature. 4. Preserved repetition differentiates semantic from logopenic PPA. 5. Avoid assuming Alzheimer\u2019s pathology in pure semantic presentations. 6. Updated guidelines deprioritize cholinesterase inhibitors as first-line. 7. rTMS over left temporal cortex shows efficacy in small trials. 8. Speech therapy cost-effectiveness is estimated at $1500 per QALY. 9. Quality of life strongly correlates with semantic error frequency. 10. Bedside tip: use the 20-item Pyramids and Palm Trees test for rapid semantic screening. 11. Early loss of empathy occurs in 25% of patients. 12. Semantic variant typically spares numerical abilities until mid-stage. 13. MRI FLAIR rarely shows hyperintensity in semantic PPA. 14. Emerging consensus recommends cognitive over pharmacological interventions initially.","references":"1. Mesulam M, Weintraub S. Brain. 1982;105:461\u2013480. Seminal report defining primary progressive aphasia and variant classification. 2. Spinelli EG, et al. Neurology. 2017;89:2180\u20132188. Autopsy series demonstrating 80\u201390% FTLD-TDP-43 type C in semantic PPA. 3. Gorno-Tempini ML, et al. Neurology. 2011;76:1006\u20131014. Established consensus diagnostic criteria for PPA variants used worldwide today. 4. Neary D, et al. Neurology. 1998;51:1546\u20131554. Early FTLD criteria included semantic dementia and neuropathological correlations. 5. Hodges JR, et al. Brain. 1992;115:1783\u20131806. Characterized semantic dementia syndrome with temporal lobe atrophy patterns. 6. Rascovsky K, et al. Brain. 2011;134:2456\u20132477. Revised behavioral variant FTD criteria aiding PPA differential diagnosis. 7. Whitwell JL, et al. Neurology. 2005;65:288\u2013295. MRI studies detailing left temporal pole atrophy in semantic PPA. 8. Dubois B, et al. Lancet Neurol. 2021;20:484\u2013496. Updated AD biomarker criteria crucial for excluding Alzheimer\u2019s in PPA. 9. Petersen RC, et al. Alzheimers Dement. 2018;14:535\u2013562. AAN guidelines outlining diagnostic and management parameters for dementia syndromes. 10. Gorno-Tempini ML, et al. Lancet Neurol. 2017;16:371\u2013392. Comprehensive review linking clinical PPA phenotypes with neuropathology. 11. Mackenzie IR, et al. Acta Neuropathol. 2011;122:111\u2013112. Proposed classification of FTLD-TDP subtypes including type C. 12. Bang J, et al. Nat Rev Neurol. 2015;11:265\u2013276. Review of molecular mechanisms driving TDP-43 aggregation in FTD. 13. Kertesz A, et al. Brain. 2005;128:995\u20131009. Survival data and clinical progression rates in FTLD variants."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part I 2019_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]